Automatic Transcranial Sonography-Based Classification of Parkinson's Disease Using a Novel Dual-Channel CNXV2-DANet.
Source check: Source checked. Not independent scientific confirmation.
Finding: Retrospective study of 588 subjects with transcranial sonography images classified for Parkinson's disease by a dual-channel CNXV2-DANet, evaluated on an independent test split. AI role: Dual-channel CNXV2-DANet deep-learning classifier. The article appeared in Bioengineering (Basel, Switzerland).
Technology: Dual-channel CNXV2-DANet deep-learning classifier
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Dual-channel CNXV2-DANet deep-learning classifier
- Test and result
- Retrospective study of 588 subjects with transcranial sonography images classified for Parkinson's disease by a dual-channel CNXV2-DANet, evaluated on an independent test split.
- Limitation / still unknown
- The result is limited to the described dataset, cohort, experimental system, or validation design; generalization beyond that scope and downstream real-world benefit are not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://mdpi-res.com/d_attachment/bioengineering/bioengineering-11-00889/article_deploy/bioengineering-11-00889.pdf · https://pubmed.ncbi.nlm.nih.gov/39329631/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.